Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo.

[1]  S. Lippard,et al.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. , 2016, Chemical reviews.

[2]  Wenbin Lin,et al.  Polymeric Micelle-Mediated Delivery of DNA-Targeting Organometallic Complexes for Resistant Ovarian Cancer Treatment. , 2015, Small.

[3]  Won Jong Kim,et al.  Polymeric biomaterials for the delivery of platinum-based anticancer drugs. , 2015, Biomaterials science.

[4]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[5]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[6]  M. Gearing,et al.  Correction: Corrigendum: Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer’s disease model , 2014, Nature Communications.

[7]  C. Alexiou,et al.  Development and characterization of magnetic iron oxide nanoparticles with a cisplatin-bearing polymer coating for targeted drug delivery , 2014, International journal of nanomedicine.

[8]  S. Dhar,et al.  Detouring of cisplatin to access mitochondrial genome for overcoming resistance , 2014, Proceedings of the National Academy of Sciences.

[9]  Christopher Poon,et al.  Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy , 2014, Nature Communications.

[10]  S. Lippard,et al.  Conjugation of vitamin E analog α-TOS to Pt(IV) complexes for dual-targeting anticancer therapy. , 2013, Chemical communications.

[11]  Ying Sun,et al.  Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. , 2013, Biomaterials.

[12]  R. Langer,et al.  Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. , 2013, ACS nano.

[13]  X. Jing,et al.  A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy. , 2012, Chemical communications.

[14]  Jianbin Tang,et al.  Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy. , 2012, Molecular pharmaceutics.

[15]  Michael M Gottesman,et al.  Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.

[16]  Toral Patel,et al.  Polymeric nanoparticles for drug delivery to the central nervous system. , 2012, Advanced drug delivery reviews.

[17]  Omid C. Farokhzad,et al.  α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. , 2012, ACS nano.

[18]  X. Jing,et al.  A complex of cyclohexane-1,2-diaminoplatinum with an amphiphilic biodegradable polymer with pendant carboxyl groups. , 2012, Acta biomaterialia.

[19]  Paul C. Wang,et al.  Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction. , 2012, Molecular pharmaceutics.

[20]  X. Jing,et al.  Biodegradable polymer - cisplatin(IV) conjugate as a pro-drug of cisplatin(II). , 2011, Biomaterials.

[21]  Omid C Farokhzad,et al.  Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo , 2011, Proceedings of the National Academy of Sciences.

[22]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[23]  S. Lippard,et al.  Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate , 2009, Proceedings of the National Academy of Sciences.

[24]  D. Nowotnik,et al.  ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic. , 2009, Advanced drug delivery reviews.

[25]  Kunihiro Tsuchida,et al.  Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns. , 2008, ACS nano.

[26]  Piero Picci,et al.  Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. , 2008, Cancer research.

[27]  S. Ganta,et al.  A review of stimuli-responsive nanocarriers for drug and gene delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[28]  C. S. Allardyce,et al.  Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. , 2005, Journal of the American Chemical Society.

[29]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[30]  D. Townsend,et al.  The role of glutathione-S-transferase in anti-cancer drug resistance , 2003, Oncogene.

[31]  S. Kohno,et al.  Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. , 1999, Free radical research.

[32]  Dutta,et al.  Inhibitors of glutathione S-transferases as therapeutic agents. , 1997, Advanced drug delivery reviews.